Symbols / MGNX $3.34 -2.62%
MGNX Chart
About
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 211.28M |
| Enterprise Value | 59.13M | Income | -74.62M | Sales | 149.50M |
| Book/sh | 0.88 | Cash/sh | 2.99 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -3.44 | PEG | — |
| P/S | 1.41 | P/B | 3.80 | P/C | — |
| EV/EBITDA | -0.90 | EV/Sales | 0.40 | Quick Ratio | 4.71 |
| Current Ratio | 5.10 | Debt/Eq | 66.13 | LT Debt/Eq | — |
| EPS (ttm) | -1.21 | EPS next Y | -0.97 | EPS Growth | — |
| Revenue Growth | 113.00% | Earnings | 2026-05-07 | ROA | -17.56% |
| ROE | -86.94% | ROIC | — | Gross Margin | -22.53% |
| Oper. Margin | -29.34% | Profit Margin | -49.91% | Shs Outstand | 63.26M |
| Shs Float | 55.59M | Short Float | 7.95% | Short Ratio | 6.38 |
| Short Interest | — | 52W High | 3.54 | 52W Low | 0.99 |
| Beta | 1.39 | Avg Volume | 1.40M | Volume | 4.05M |
| Target Price | $3.60 | Recom | Hold | Prev Close | $3.43 |
| Price | $3.34 | Change | -2.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.60
Mean price target
2. Current target
$3.34
Latest analyst target
3. DCF / Fair value
$-16.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.34
Low
$2.00
High
$5.00
Mean
$3.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-10 | main | Barclays | Overweight → Overweight | $4 |
| 2025-11-03 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2025-08-15 | main | Leerink Partners | Outperform → Outperform | $5 |
| 2025-05-20 | main | B. Riley Securities | Neutral → Neutral | $3 |
| 2025-05-14 | main | Stifel | Hold → Hold | $5 |
| 2025-05-14 | main | Barclays | Overweight → Overweight | $3 |
| 2025-03-25 | main | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-11-07 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2024-11-06 | reit | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2024-09-18 | reit | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2024-08-21 | reit | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2024-08-15 | main | Citigroup | Buy → Buy | $14 |
| 2024-08-07 | main | BMO Capital | Market Perform → Market Perform | $5 |
| 2024-08-01 | down | BTIG | Buy → Neutral | — |
| 2024-08-01 | reit | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2024-07-31 | main | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-07-31 | main | Barclays | Overweight → Overweight | $8 |
| 2024-07-31 | down | Guggenheim | Buy → Neutral | — |
| 2024-07-31 | down | B. Riley Securities | Buy → Neutral | $5 |
| 2024-07-29 | main | Barclays | Overweight → Overweight | $9 |
- Cancer biotech MacroGenics lines up 2026 trial data, funds into 2027 - Stock Titan Mon, 09 Mar 2026 20
- Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock - MarketBeat ue, 10 Mar 2026 15
- MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance Mon, 09 Mar 2026 21
- MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies - Stocktwits ue, 10 Mar 2026 13
- Barclays Raises Price Target for Macrogenics (MGNX) to $4.00, Maintains 'Overweight' Rating | MGNX Stock News - GuruFocus ue, 10 Mar 2026 14
- MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative - simplywall.st Wed, 11 Mar 2026 03
- MacroGenics drops after FDA partial clinical hold on lead program - Seeking Alpha ue, 24 Feb 2026 08
- Stifel reiterates MacroGenics stock rating with $4 price target - Investing.com Australia Wed, 11 Mar 2026 01
- 12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga ue, 10 Mar 2026 17
- MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewswire hu, 26 Feb 2026 08
- Cancer drug developer MacroGenics lines up March investor talks - Stock Titan hu, 26 Feb 2026 08
- MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat ue, 10 Mar 2026 14
- MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com ue, 10 Mar 2026 01
- MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets (NASDAQ:MGNX) - Seeking Alpha Fri, 05 Sep 2025 07
- FDA halts new enrollment in cancer trial after severe side effects - Stock Titan Mon, 23 Feb 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 21165 | — | — | KOENIG SCOTT | Director | — | 2026-02-13 00:00:00 | D | nan |
| 1 | 16665 | — | — | BONVINI EZIO | Officer | — | 2026-02-13 00:00:00 | D | nan |
| 2 | 16665 | — | — | RISSER ERIC BLASIUS | Chief Executive Officer | — | 2026-02-13 00:00:00 | D | nan |
| 3 | 13332 | — | — | SPITZNAGEL THOMAS | Officer | — | 2026-02-13 00:00:00 | D | nan |
| 4 | 13332 | — | — | PETERS JEFFREY STUART | General Counsel | — | 2026-02-13 00:00:00 | D | nan |
| 5 | 1095 | — | — | SMITH BETH ANN | Officer and Treasurer | — | 2026-02-13 00:00:00 | D | nan |
| 6 | 14999 | — | — | KARRELS JAMES | Chief Financial Officer | — | 2026-02-13 00:00:00 | D | nan |
| 7 | 15831 | — | — | KOENIG SCOTT | Director | — | 2026-02-06 00:00:00 | D | nan |
| 8 | 18167 | — | — | BONVINI EZIO | Officer | — | 2026-02-06 00:00:00 | D | nan |
| 9 | 17834 | — | — | RISSER ERIC BLASIUS | Chief Executive Officer | — | 2026-02-06 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 7.61M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -93.62M | -148.91M | -107.89M | -190.86M |
| TotalUnusualItems | 36.25M | 150.93M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 36.25M | 150.93M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -66.97M | -9.06M | -119.76M | -202.12M |
| ReconciledDepreciation | 7.54M | 9.64M | 11.87M | 11.26M |
| ReconciledCostOfRevenue | 12.30M | 8.22M | 7.38M | 2.65M |
| EBITDA | -57.37M | 2.02M | -107.89M | -190.86M |
| EBIT | -64.91M | -7.63M | -119.76M | -202.12M |
| NetInterestIncome | 8.31M | 8.26M | 1.66M | 680.00K |
| InterestExpense | 1.11M | 1.43M | 0.00 | 0.00 |
| InterestIncome | 9.42M | 9.69M | 1.66M | 680.00K |
| NormalizedIncome | -95.60M | -159.99M | -119.76M | -202.12M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -66.97M | -9.06M | -119.76M | -202.12M |
| TotalExpenses | 258.92M | 225.44M | 271.44M | 278.44M |
| TotalOperatingIncomeAsReported | -110.58M | -168.24M | -121.42M | -202.79M |
| DilutedAverageShares | 62.62M | 61.93M | 61.43M | 59.94M |
| BasicAverageShares | 62.62M | 61.93M | 61.43M | 59.94M |
| DilutedEPS | -1.07 | -0.15 | -1.95 | -3.37 |
| BasicEPS | -1.07 | -0.15 | -1.95 | -3.37 |
| DilutedNIAvailtoComStockholders | -66.97M | -9.06M | -119.76M | -202.12M |
| NetIncomeCommonStockholders | -66.97M | -9.06M | -119.76M | -202.12M |
| NetIncome | -66.97M | -9.06M | -119.76M | -202.12M |
| NetIncomeIncludingNoncontrollingInterests | -66.97M | -9.06M | -119.76M | -202.12M |
| NetIncomeContinuousOperations | -66.97M | -9.06M | -119.76M | -202.12M |
| TaxProvision | 944.00K | 0.00 | 0.00 | |
| PretaxIncome | -66.02M | -9.06M | -119.76M | -202.12M |
| OtherIncomeExpense | 36.25M | 150.93M | 1.66M | 680.00K |
| OtherNonOperatingIncomeExpenses | 1.66M | 680.00K | ||
| SpecialIncomeCharges | 36.25M | 150.93M | 0.00 | 0.00 |
| GainOnSaleOfBusiness | 36.25M | 150.93M | 0.00 | 0.00 |
| NetNonOperatingInterestIncomeExpense | 8.31M | 8.26M | 1.66M | 680.00K |
| InterestExpenseNonOperating | 1.11M | 1.43M | 0.00 | 0.00 |
| InterestIncomeNonOperating | 9.42M | 9.69M | 1.66M | 680.00K |
| OperatingIncome | -110.58M | -168.24M | -121.42M | -202.79M |
| OperatingExpense | 246.62M | 217.22M | 264.05M | 275.79M |
| OtherOperatingExpenses | -1.62M | -1.56M | -1.92M | -1.80M |
| ResearchAndDevelopment | 177.19M | 166.58M | 207.03M | 214.58M |
| SellingGeneralAndAdministration | 71.05M | 52.19M | 58.95M | 63.01M |
| GrossProfit | 136.04M | 48.97M | 142.63M | 72.99M |
| CostOfRevenue | 12.30M | 8.22M | 7.38M | 2.65M |
| TotalRevenue | 148.34M | 57.19M | 150.02M | 75.64M |
| OperatingRevenue | 148.34M | 57.19M | 150.02M | 75.64M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 62.82M | 62.07M | 61.70M | 61.31M |
| ShareIssued | 62.82M | 62.07M | 61.70M | 61.31M |
| TotalDebt | 37.46M | 33.97M | 34.83M | 25.47M |
| TangibleBookValue | 116.06M | 152.61M | 142.01M | 239.62M |
| InvestedCapital | 116.06M | 152.61M | 142.01M | 239.62M |
| WorkingCapital | 161.96M | 195.23M | 173.57M | 204.98M |
| NetTangibleAssets | 116.06M | 152.61M | 142.01M | 239.62M |
| CapitalLeaseObligations | 37.46M | 33.97M | 34.83M | 25.47M |
| CommonStockEquity | 116.06M | 152.61M | 142.01M | 239.62M |
| TotalCapitalization | 116.06M | 152.61M | 142.01M | 239.62M |
| TotalEquityGrossMinorityInterest | 116.06M | 152.61M | 142.01M | 239.62M |
| StockholdersEquity | 116.06M | 152.61M | 142.01M | 239.62M |
| GainsLossesNotAffectingRetainedEarnings | 4.00K | -6.00K | -5.00K | -61.00K |
| OtherEquityAdjustments | 4.00K | -6.00K | -5.00K | -61.00K |
| RetainedEarnings | -1.17B | -1.10B | -1.09B | -973.94M |
| AdditionalPaidInCapital | 1.29B | 1.25B | 1.24B | 1.21B |
| CapitalStock | 628.00K | 621.00K | 617.00K | 613.00K |
| CommonStock | 628.00K | 621.00K | 617.00K | 613.00K |
| TotalLiabilitiesNetMinorityInterest | 145.60M | 145.81M | 138.46M | 95.63M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 90.07M | 89.70M | 89.84M | 21.05M |
| OtherNonCurrentLiabilities | 1.97M | 258.00K | 258.00K | 258.00K |
| NonCurrentDeferredLiabilities | 55.50M | 59.24M | 59.48M | 0.00 |
| NonCurrentDeferredRevenue | 55.50M | 59.24M | 59.48M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 32.60M | 30.20M | 30.11M | 20.79M |
| LongTermCapitalLeaseObligation | 32.60M | 30.20M | 30.11M | 20.79M |
| CurrentLiabilities | 55.53M | 56.11M | 48.61M | 74.58M |
| CurrentDeferredLiabilities | 16.32M | 21.65M | 9.99M | 20.65M |
| CurrentDeferredRevenue | 16.32M | 21.65M | 9.99M | 20.65M |
| CurrentDebtAndCapitalLeaseObligation | 4.86M | 3.77M | 4.73M | 4.68M |
| CurrentCapitalLeaseObligation | 4.86M | 3.77M | 4.73M | 4.68M |
| PayablesAndAccruedExpenses | 34.35M | 30.68M | 33.90M | 49.26M |
| CurrentAccruedExpenses | 29.33M | 24.24M | 29.00M | 33.76M |
| Payables | 5.01M | 6.44M | 4.90M | 15.50M |
| AccountsPayable | 5.01M | 6.44M | 4.90M | 15.50M |
| TotalAssets | 261.65M | 298.42M | 280.47M | 335.25M |
| TotalNonCurrentAssets | 44.16M | 47.08M | 58.29M | 55.69M |
| OtherNonCurrentAssets | 1.56M | 1.39M | 1.38M | 1.40M |
| NetPPE | 42.61M | 45.69M | 56.91M | 54.29M |
| AccumulatedDepreciation | -88.69M | -88.39M | -84.08M | -72.81M |
| GrossPPE | 131.30M | 134.09M | 141.00M | 127.10M |
| Leases | 44.10M | 48.62M | 52.97M | 51.06M |
| ConstructionInProgress | 1.22M | 1.11M | 356.00K | 630.00K |
| OtherProperties | 70.65M | 70.30M | 73.81M | 62.31M |
| MachineryFurnitureEquipment | 15.33M | 14.06M | 13.86M | 13.11M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 217.49M | 251.34M | 222.18M | 279.56M |
| OtherCurrentAssets | 11.51M | 9.95M | 10.16M | 21.17M |
| PrepaidAssets | 21.17M | |||
| Inventory | 0.00 | 1.22M | 1.45M | 4.39M |
| FinishedGoods | 960.00K | 1.04M | 459.00K | |
| WorkInProcess | 261.00K | 409.00K | 3.93M | |
| Receivables | 4.31M | 10.37M | 56.22M | 10.39M |
| AccountsReceivable | 4.31M | 10.37M | 56.22M | 10.39M |
| CashCashEquivalentsAndShortTermInvestments | 201.67M | 229.81M | 154.35M | 243.62M |
| OtherShortTermInvestments | 18.83M | 128.85M | 45.46M | 120.15M |
| CashAndCashEquivalents | 182.84M | 100.96M | 108.88M | 123.47M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -72.08M | -79.97M | -90.58M | -150.03M |
| IssuanceOfCapitalStock | 0.00 | 616.00K | 1.08M | 117.82M |
| CapitalExpenditure | -3.71M | -1.76M | -3.62M | -6.20M |
| IncomeTaxPaidSupplementalData | 944.00K | 0.00 | 0.00 | |
| EndCashPosition | 182.84M | 100.96M | 108.88M | 123.47M |
| BeginningCashPosition | 100.96M | 108.88M | 123.47M | 181.13M |
| ChangesInCash | 81.88M | -7.93M | -14.59M | -57.66M |
| FinancingCashFlow | 960.00K | 150.36M | 1.66M | 122.78M |
| CashFlowFromContinuingFinancingActivities | 960.00K | 150.36M | 1.66M | 122.78M |
| NetOtherFinancingCharges | -2.48M | 149.19M | ||
| ProceedsFromStockOptionExercised | 3.44M | 553.00K | 574.00K | 4.96M |
| NetCommonStockIssuance | 0.00 | 616.00K | 1.08M | 117.82M |
| CommonStockIssuance | 0.00 | 616.00K | 1.08M | 117.82M |
| InvestingCashFlow | 149.30M | -80.08M | 70.72M | -36.61M |
| CashFlowFromContinuingInvestingActivities | 149.30M | -80.08M | 70.72M | -36.61M |
| NetOtherInvestingChanges | 40.00M | |||
| NetInvestmentPurchaseAndSale | 112.84M | -78.38M | 74.34M | -30.41M |
| SaleOfInvestment | 190.03M | 161.30M | 194.94M | 200.80M |
| PurchaseOfInvestment | -77.18M | -239.68M | -120.60M | -231.21M |
| NetPPEPurchaseAndSale | -3.55M | -1.70M | -3.62M | -6.20M |
| SaleOfPPE | 160.00K | 64.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -3.71M | -1.76M | -3.62M | -6.20M |
| OperatingCashFlow | -68.37M | -78.20M | -86.96M | -143.83M |
| CashFlowFromContinuingOperatingActivities | -68.37M | -78.20M | -86.96M | -143.83M |
| ChangeInWorkingCapital | 1.39M | 53.32M | -6.13M | 17.57M |
| ChangeInOtherWorkingCapital | -9.58M | 11.42M | 34.78M | 9.26M |
| ChangeInOtherCurrentLiabilities | 5.20M | -861.00K | 9.36M | -3.52M |
| ChangeInOtherCurrentAssets | -7.00K | -14.04M | 3.23M | |
| ChangeInPayablesAndAccruedExpense | 3.47M | -3.54M | -15.50M | 6.52M |
| ChangeInAccruedExpense | 5.00M | -4.82M | -4.64M | -607.00K |
| ChangeInPayable | -1.53M | 1.28M | -10.86M | 7.12M |
| ChangeInAccountPayable | -1.53M | 1.28M | -10.86M | 7.12M |
| ChangeInPrepaidAssets | -1.57M | 215.00K | 11.01M | -4.19M |
| ChangeInInventory | -2.19M | 230.00K | 55.00K | -6.42M |
| ChangeInReceivables | 6.06M | 45.85M | -45.84M | 12.70M |
| ChangesInAccountReceivables | 6.06M | 45.85M | -45.84M | 12.70M |
| OtherNonCashItems | -661.00K | -145.59M | 6.22M | 4.72M |
| StockBasedCompensation | 29.44M | 18.37M | 20.44M | 23.13M |
| AmortizationOfSecurities | -2.81M | -5.00M | 403.00K | 1.61M |
| DepreciationAmortizationDepletion | 7.54M | 9.64M | 11.87M | 11.26M |
| DepreciationAndAmortization | 7.54M | 9.64M | 11.87M | 11.26M |
| OperatingGainsLosses | -36.31M | 111.00K | ||
| NetIncomeFromContinuingOperations | -66.97M | -9.06M | -119.76M | -202.12M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MGNX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|